Overcoming acquired resistance to targeted therapies in lung cancer - European Medical Journal

Overcoming acquired resistance to targeted therapies in lung cancer

Oncology

At the European Cancer Congress (ECC) 2015, David Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, Aurora, CO, explains that strategies to manage progression in patients with non-small cell lung cancer (NSCLC) should be tailored to individual patients, as there may be a need to address pharmacologic issues or the molecular emergence of new resistant clones.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now